Effect of cumin and lemon on obesity

Effect of oral soft gel containing lemon and cumin essential oil in various doses on weight in subjects with overweight and obesity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015030812438N10

Enrollment

Registered

2015-03-25

Start date

2015-03-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity. Obesity, unspecified

Interventions

Intervention 1: Intervention group: Oral soft gel containing lemon and cumin essential oil, 25 mg, twice a day, for 8 weeks orally. Intervention 2: Intervention group: Oral soft gel containing lemon a

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Overweight or obesity (BMI = 25 kg/m2) Aged 18-50 years

Exclusion criteria

Exclusion criteria: BMI < 25 kg/m2 Hypertension Thyroid disorders Diabetes Cardiovascular disorders Pregnancy and lactation The use of hormonal or anti-obesity medications

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: Baseline and End-of-trial. Method of measurement: scale.;Body Mass Index. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using formula.	—

Secondary

Measure	Time frame
Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.	—

Measure

Time frame

Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.M.Taghizadeh

Kashan University of Medical Sciences

taghizadeh_m@kaums.ac.ir+98 36 1555 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026